华人健康 reported revenue of ¥2.82B for the period ended 2026-06-30, +12.8% year on year. Net income was ¥0.15B, a 5.3% net margin on a 34.7% gross margin. The largest revenue line is 中西成药 at 82% of the total. Free cash flow for the period was ¥0.09B.
| Item | Amount | Y/Y |
|---|---|---|
| Revenue | ¥2.82B | +12.8% |
| Gross profit | ¥0.98B | — |
| Operating income | ¥0.20B | — |
| Net income | ¥0.15B | +32.9% |
| Gross margin | 34.7% | Net margin 5.3% |
| Revenue Q/Q | -1.2% | — |
| Segment | Revenue | Share |
|---|---|---|
| 中西成药 | ¥2.32B | 82.0% |
| 其他主营业务 | ¥0.45B | 16.0% |
| 其他(补充) | ¥0.06B | 2.1% |
| Item | Amount | % of revenue |
|---|---|---|
| Cost of revenue | ¥1.84B | 65.3% |
| R&D | ¥0.02B | 0.6% |
| SG&A | ¥0.73B | 26.0% |
| Tax & other | ¥0.05B | 1.9% |
| Item | Amount |
|---|---|
| Total assets | ¥5.47B |
| Total liabilities | ¥3.29B |
| Shareholders' equity | ¥2.17B |
| Equity / assets | 39.8% |
| Operating cash flow | ¥0.11B |
| Capital expenditure | ¥0.02B |
| Free cash flow | ¥0.09B |
| Cash conversion (OCF / net income) | 276% |
The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.
安培龙 ・ 协昌科技 ・ 阿莱德 ・ 波长光电 ・ 世纪恒通 ・ 森泰股份 ・ 泓淋电力 ・ 福事特 ・ 开创电气 ・ 天溯计量 ・ 盘古智能 ・ 钧崴电子
Source: Eastmoney · This page shows public filing data only, not investment advice. · Browse all companies